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Background: In the general population, high serum uric acid concentration is a risk factor for gout. It is
unknown whether donating a kidney increases a living donor’s risk of gout as serum uric acid concentration
increases in donors after nephrectomy.
Study Design: Retrospective matched cohort study using large health care databases.
Setting & Participants: We studied living kidney donors who donated in 1992 to 2010 in Ontario, Canada.
Matched nondonors were selected from the healthiest segment of the general population. 1,988 donors and
19,880 matched nondonors were followed up for a median of 8.4 (maximum, 20.8) years.
Predictor: Living kidney donor nephrectomy.
Outcomes: The primary outcome was time to a diagnosis of gout. The secondary outcome in a subpop-
ulation was receipt of medications typically used to treat gout (allopurinol or colchicine).
Measurements: We assessed the primary outcome with health care diagnostic codes.
Results: Donors compared with nondonors were more likely to be given a diagnosis of gout (3.4% vs 2.0%;
3.5 vs 2.1 events/1,000 person-years; HR, 1.6; 95% CI, 1.2-2.1; P, 0.001). Similarly, donors compared with
nondonors were more likely to receive a prescription for allopurinol or colchicine (3.8% vs 1.3%; OR, 3.2; 95%
CI, 1.5-6.7; P5 0.002). Results were consistent in multiple additional analyses.
Limitations: The primary outcome was assessed using diagnostic codes in health care databases. Lab-
oratory values for serum uric acid and creatinine in follow-up were not available in our data sources.
Conclusions: The findings suggest that donating a kidney modestly increases an individual’s absolute long-
term incidence of gout. This unique observation should be corroborated in future studies.
Am J Kidney Dis. 65(6):925-932.ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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transplantation; uric acid.High serum uric acid concentration is a potent riskfactor for gout, for which the 10-year incidence
rates are estimated to be 49%, 5%, and 1% for uric
acid levels $ 9, 7.0 to 8.9, and , 7.0 mg/dL,
respectively.1,2 A decline in glomerular ﬁltration rate
(GFR) results in less uric acid excretion and a higher
serum uric acid concentration.3,4 These changes are
evident with the 25% to 40% reduction in GFR that
occurs after living kidney donation.5-9 As early as 6
months after nephrectomy, donors versus nondonor1Department of Medicine, Division of Nephrology,
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y Dis. 2015;65(6):925-932controls demonstrate an 8.2% higher serum uric acid
level (mean values of 5.36 1.1 [standard deviation]
vs 4.9 6 1.2 mg/dL; P , 0.001) and a 20% higher
serum uric acid level a mean of 7 years after ne-
phrectomy (Table S1, available as online supple-
mentary material); mean uric acid level is 1.0 mg/dL
higher in donors compared with nondonor con-
trols.8,10 However, whether donating a kidney
appreciably increases a person’s risk of gout is un-
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Lam et alwhether kidney donors have a higher risk of gout than
nondonors with similar indicators of baseline health.
METHODS
Design and Setting
We conducted a retrospective matched cohort study using
manual chart review and linked health care databases in Ontario,
Canada, where citizens have universal access to hospital care and
physician services. The reporting of this study followed guidelines
for observational studies.11 The research ethics board approved the
prespeciﬁed protocol and waived the need for informed consent.
Data Sources
We ascertained patient characteristics, covariate information,
and outcome data from records in 7 linked databases. Trillium Gift
of Life Network is Ontario’s organ and tissue donation registry and
captures information for all living kidney donors in the province at
the time of donation. We supplemented the data at this registry by
manually reviewing perioperative charts of all living kidney donors
who underwent donor nephrectomy at 1 of 5 major transplantation
centers in Ontario in 1992 through 2010 to ensure data accuracy
and completeness. Demographics and vital status information were
retrieved from Ontario’s Registered Persons Database. We used the
Ontario Drug Beneﬁt database to identify prescription drug use.
This database contains highly accurate records of outpatient pre-
scriptions dispensed to all patients 65 years or older, with a basic
error rate , 1%.12 Diagnostic and procedural information during
hospital admissions was gathered from the Canadian Institute for
Health Information Discharge Abstract Database (CIHI-DAD) and
Same Day Surgery (CIHI-SDS), whereas information regarding
emergency department visits was gathered from the National
Ambulatory Care Reporting System. The Ontario Health Insurance
Plan database contains health claims for both inpatient and
outpatient physician services. These databases have been used
extensively for epidemiologic and health services research,
including the study of living kidney donor outcomes.13-19
Population
Donors
We included all permanent residents who donated a kidney from
July 1, 1992, through April 30, 2010, at any of the 5 major
transplantation centers in Ontario. The date of nephrectomy served
as the start date for follow-up and was designated the index date.
Prior to matching, 35 living kidney donors with a predonation
diagnosis of gout or a prescription for a medication typically used
for the treatment of gout (eg, allopurinol or colchicine) were
excluded. This was done to assess de novo gout in follow-up.
There were too few donors with predonation gout to permit
meaningful analyses of their outcomes after donation. We also
excluded donors with recognized risk factors for gout, such as
those with a predonation diagnosis of alcoholism (n 5 10) or those
with evidence of a prescription for medications that may increase
uric acid levels (n 5 86), such as thiazides.
Healthy Nondonors
Selecting the appropriate nondonors with whom donors can be
compared is central to any study reporting risks associated with
donor nephrectomy.20 Donors undergo a rigorous medical
screening and selection process and thus are inherently healthier
than the general population. To address this issue, we used tech-
niques of restriction andmatching to select the healthiest segment of
the general population. We randomly assigned an index date to the
entire Ontario adult general population according to the distribution
of index dates in the donors. We then identiﬁed comorbid condi-
tions and measures of health care access from the beginning of926available database records (July 1, 1991) to the index date. This
provided an average of 12 years of medical records for baseline
assessment, with 98.4% of individuals having at least 2 years of data
for review. Among the general population, we excluded adults with
a history of gout (n 5 210,814) or any medical conditions prior to
the index date that could preclude donation, including diabetes and
hypertension (Table S2). Those who had a nephrectomy, kidney
transplantation, kidney biopsy, dialysis, or a previous nephrology
consultation also were excluded. Furthermore, we excluded any
individual who had evidence of frequent physician visits (.4 visits
in the previous 2 years) or who failed to see a physician at least once
in the previous 2 years. The latter criterion was applied to ensure
that healthy nondonors in our study were accessing physicians for
routine health care needs, including preventive health measures.
From a total of 9,484,623 Ontarians during the period of interest,
this selection process resulted in the exclusion of 45.2% of adults
(n 5 4,291,484) as eligible nondonors. From the remaining adults,
we matched 10 healthy nondonors to each donor based on age
(within 2 years), sex, index date (within 6 months), rural
(population, 10,000) or urban residence, and income (categorized
into ﬁfths of average neighborhood income).
Outcomes
All patients were followed up until death, emigration from the
province, or the end of the study period (March 31, 2013). The
primary outcome was time to the ﬁrst health care encounter
(physician visit, emergency department visit, or hospitalization) in
follow-up atwhich a diagnostic code of goutwas recorded in a health
care database by medical coders or those submitting claims for
physician reimbursement (Table S2). The secondary outcome was
receipt of a prescription for allopurinol or colchicine, 2 medications
typically used to treat gout. This secondary outcome was examined
in the subpopulation that reached 65 years or older in follow-up.
Statistical Analysis
We compared standardized differences in baseline characteris-
tics between donors and healthy nondonors. Differences . 10%
suggest meaningful imbalance.21 We used Cox proportional haz-
ards regression models, stratiﬁed on matched sets, to calculate the
hazard ratio (HR) with 95% conﬁdence interval (CI) for the time to
ﬁrst gout diagnosis. The proportional hazards assumption was not
violated (nonsigniﬁcant donor 3 log [follow-up time] interaction
term; P 5 0.5). We expressed the risk of developing an outcome in
both relative and absolute terms. Absolute risk also was expressed
as the number needed to harm (ie, the reciprocal of the absolute
risk increase). This measure indicates how many individuals need
to donate a kidney for 1 patient to experience an event, who
otherwise would not have been harmed if all individuals did not
donate a kidney (a lower number indicating greater harm). The
number needed to harm was calculated for ease of interpretation
and not to imply causality. In the subpopulation in which all in-
dividuals in a matched set reached 65 years or older in follow-up,
we used conditional logistic regression accounting for matched
sets to calculate the odds ratio (OR) and 95% CI for receipt of a
prescription for allopurinol or colchicine. We repeated the primary
analysis in 4 prespeciﬁed subgroups deﬁned by the presence or
absence of a family history of kidney disease, median age at index
date (#43 vs .43 years), sex, and index date (1992-2003 [median
follow-up, 13.6 (interquartile range [IQR], 11.4-16.4) years] vs
2004-2010 [median follow-up, 5.8 (IQR, 4.3-7.3) years]). Infor-
mation for family history of kidney disease was available for only
donors (living related vs living unrelated donor), and in each
subgroup analysis, sets of nondonors were categorized according
to the characteristic of their matched donor (so as not to break
matched sets in subgroup analysis). We examined whether
subgroup-speciﬁc rate ratios differed among subgroups using a
series of pairwise standard z tests. We examined the characteristicsAm J Kidney Dis. 2015;65(6):925-932
Gout in Living Kidney Donorsassociated with a diagnosis of gout separately in donors and
healthy nondonors using Cox proportional hazards regression
models. These characteristics were age (per 5 years older), sex,
rural or urban residence, income quintile, and index date (per 1
year later). In donors, we also examined whether a family history
of kidney disease or the predonation estimated GFR (eGFR) was
associated with a diagnosis of gout.
We conducted all analyses with SAS, version 9.3 (SAS Institute




Baseline characteristics for 1,988 living kidney
donors and 19,880 matched healthy nondonors are
shown in Table 1. Median age was 43 (IQR, 35-51)
years and 61% were women. Unsurprisingly, do-
nors had more physician visits during the year prior
to the index date compared with nondonors because
these visits are a required part of the donor evalu-
ation process. Most living kidney donors were
siblings of the recipients (34.4%), followed by
spouses (19.2%), parents (13.7%), and children
(13.0%). Before donation, median serum creatinine
level was 0.8 (IQR, 0.7-1.0) mg/dL and eGFR wasTable 1. Characteristics of Kidney Donors and Matched Healthy





Age (y) 43 [35-51] 43 [35-50]
Female sex 1,217 (61.2) 12,170 (61.2)
Rural town 276 (13.9) 2,760 (13.9)
Income quintile
1st: lowest 282 (14.2) 2,802 (14.1)
2nd 342 (17.2) 3,484 (17.5)
3rd: middle 427 (21.5) 4,401 (22.1)
4th 474 (23.8) 4,656 (23.4)
5th: highest 463 (23.3) 4,537 (22.8)
Physician visits in prior yeara 5 [2-8] 1 [0-2]
Year of cohort entry
1992-1997 354 (17.8) 3,550 (17.9)
1998-2003 648 (32.6) 6,456 (32.5)
2004-2010 986 (49.6) 9,874 (49.7)
Note: Values for categorical variables are given as number
(percentage); values for continuous variables, as median
[interquartile range]. Time of cohort entry also is referred to as
the index date. For living kidney donors, this was the date of
nephrectomy and was randomly assigned to nondonors to
establish the time that follow-up began.
aIndicates a standardized difference between donors and
healthy nondonors . 10%. Standardized differences are less
sensitive to sample size than traditional hypothesis tests. They
provide a measure of difference between groups divided by
pooled standard deviation; a value . 10% is interpreted as a
meaningful difference between groups. As expected, donors had
more physician visits in the year prior to the index date
compared with healthy nondonors; such visits are a necessary
part of the donor evaluation process.
Am J Kidney Dis. 2015;65(6):925-93299 (IQR, 87-109) mL/min/1.73 m2 (calculated us-
ing the CKD-EPI [Chronic Kidney Disease Epide-
miology Collaboration] creatinine equation22).
Median follow-up was 8.4 years (in donors, 8.8
years; in healthy nondonors, 8.4 years; maximum,
20.8 years), with 844 donors and 8,145 healthy non-
donors having more than 10 years of follow-up. Of
21,868 total individuals, 429 (2.0%) were censored at
the time of death; 1,507 (6.9%), at the time of pro-
vincial emigration; 19,475 (89.1%), at the time they
reached last follow-up (March 31, 2013); and the rest,
at the time of their ﬁrst diagnosis of gout. Total
person-years of follow-up were 205,432 (donors,
19,063; nondonors, 186,369).
Outcomes
There were 457 episodes of gout (in donors, 67; in
healthy nondonors, 390; Table 2; Fig 1). The risk of
gout was higher in donors than matched healthy
nondonors (3.4% vs 2.0%; 3.5 vs 2.1 events/1,000
person-years; HR, 1.6; 95% CI, 1.2-2.1; P , 0.001).
At an 8-year median follow-up, the absolute risk
difference was 1.4% (95% CI, 0.6%-2.2%) and
number needed to harm was 71 (95% CI, 45-170).
Median time to ﬁrst gout diagnosis was 5.7 (IQR, 2.8-
9.9; range, 0.04-20.3) years.
We assessed prescription medications in the sub-
population in which all individuals in a matched set
reached 65 years or older in follow-up (262 donors
and 2,620 healthy nondonors; Table S3). The risk of
receiving allopurinol or colchicine was higher in
living kidney donors than in matched healthy non-
donors (10/262 [3.8%] vs 33/2,620 [1.3%]; OR, 3.2;
95% CI, 1.5-6.7; P 5 0.002).
Figure 2 shows subgroup analyses deﬁned by a
family history of kidney disease, age at index date,
sex, and date of index date. The overall association of
a higher risk of gout in donors versus matched healthy
nondonors did not differ signiﬁcantly across any of
these subgroups (P for interaction range 5 0.05-0.3).
When donors and matched healthy nondonors were
examined separately, in both groups, older age and
male sex were associated with higher risk of gout
(Table 3). In donors, family history of kidney disease
was not associated with higher risk of gout, and the
association with different strata of lower predonation
eGFRs was inconsistent (Table 4).
Additional Analyses
The primary association proved robust in additional
analyses. First, we redeﬁned the primary outcome by
the presence of 2 separate days with diagnostic codes
for gout (vs 1 day as done in the primary analysis), for
which the date of the second code deﬁned an event.
There were 222 episodes of gout (in donors, 38; in
healthy nondonors, 184). The risk of gout remained927
Table 2. Gout Among Kidney Donors and Matched Healthy Nondonors
Gout Diagnosis Receipt of Gout Medicationsa
Donors (n 5 1,988) Healthy Nondonors (n 5 19,880) Donors (n 5 262) Healthy Nondonors (n 5 2,620)
No. of events 67 (3.4) 390 (2.0) 10 (3.8) 33 (1.3)
Events per 1,000 person-y 3.5 2.1 — —
Model-based rate ratiob 1.6 (1.2-2.1)c 1.00 (reference) 3.2 (1.5-6.7)d 1.00 (reference)
Note: Values are given as number, number (percentage), or value (95% CI).
Abbreviation: CI, confidence interval.
aThis subpopulation represents matched sets in which all individuals in the set reached 65 years or older in follow-up (when all
Ontario citizens participate in the universal prescription drug plan).
bCox proportional hazard regression models, stratified on matched sets, were used to calculate the hazard ratio with 95% CI for the
primary outcome of gout diagnosis, and conditional logistic regression for matched sets was used to calculate the odds ratio and 95%
CI for the secondary outcome of receipt of gout medications.
cP, 0.001.
dP 5 0.002.
Lam et alhigher in donors versus healthy nondonors (1.9% vs
0.9%; 2.0 vs 1.0 events/1,000 person-years; HR, 2.1;
95% CI, 1.5-3.0; P , 0.001).
Second, to test the speciﬁcity of our ﬁndings, we
examined whether the risk of rheumatoid arthritis
differed in donors and healthy nondonors. Because
there is no plausible reason why living donation
would increase the risk of rheumatoid arthritis, we
reasoned that a null association with this outcome
would enhance causal inference in our gout analyses.
The risk of rheumatoid arthritis was no different in
donors than in healthy nondonors (2.7% vs 2.1%; 2.7
vs 2.2 events/1,000 person-years; HR, 1.2; 95% CI,
0.9-1.7; P 5 0.2).
Third, we were concerned that donors would see
their physicians in follow-up for routine care moreFigure 1. Cumulative percentage of living kidney donors and
matched healthy nondonors with a diagnosis of gout. Abbrevia-
tion: CI, confidence interval.
928often than healthy nondonors, which might bias the
ascertainment of gout. Thus, we restricted the analysis
to matched sets of patients who were gout free for the
ﬁrst 3 years after their index date and followed up this
subpopulation for a diagnosis of gout, adjusting for
the number of physician visits in the prior 2 years.
Donors compared with healthy nondonors had more
physician visits during this period (median visits, 7.5
[IQR, 3-14] vs 4 [IQR, 1-8]). However, there was no
substantial attenuation of the higher risk of gout in
donors compared with healthy nondonors after
adjustment for the number of physician visits (2.4%
vs 1.5%; 2.3 vs 1.5 events/1,000 person-years; HR,
1.5; 95% CI, 1.0-2.1; P 5 0.04). In another analysis,
we assessed the receipt of prescription nonsteroidal
anti-inﬂammatory drugs (NSAIDs) to consider the
possibility that donors were instructed to avoid
NSAIDs in favor of other gout medications. The
likelihood of receiving an NSAID was no different in
donors and healthy nondonors (32.8% vs 29.5%; OR,
1.2; 95% CI, 0.9-1.6; P 5 0.2).
We also performed other analyses to put the results
into context. First, rather than matching donors to the
healthiest segment of the general population, we
matched donors to the general population (for which
the only exclusion was a prior episode of gout;
Tables S4 and S5). The risk of gout was not statisti-
cally different in donors compared with general
population nondonors (67/1,988 [3.4%] vs 540/
19,880 [2.7%]; 3.5 vs 2.9 events/1,000 person-years;
HR, 1.2; 95% CI, 0.9-1.6; P 5 0.1; Fig S1). Simi-
larly, the risk of receiving a prescription for allopu-
rinol or colchicine was not statistically different in
donors compared with general population nondonors.
Second, we compared the cumulative probability of
gout in the 20 years after the index date, stratifying
results by donation status and age at index date
(20, 40, or 60 years). The 20-year cumulative prob-
ability of gout was higher in donors versus healthyAm J Kidney Dis. 2015;65(6):925-932
Figure 2. Influence of family history of kidney failure, age at index date, sex, and date of index date (duration of follow-up) on pri-
mary outcome of a diagnosis of gout in living kidney donors versus healthy nondonors. Information for family history of kidney disease
was available for only donors (living related vs living unrelated donor) and in each subgroup analysis, sets of nondonors were cate-
gorized according to the characteristic of their matched donor (so as not to break matched sets in subgroup analysis). Although
61% of donors had a first-degree relative with kidney failure, we assume that few nondonors had a similar family history, although
this information was not available for nondonors. Individuals with an index date of 1992 to 2003 had median follow-up of 13.6 (inter-
quartile range [IQR], 11.4 to 16.4) years, and individuals with an index date of 2004 to 2010 had median follow-up of 5.8 (IQR, 4.3 to
7.3) years. Abbreviation: CI, confidence interval.
Gout in Living Kidney Donorsnondonors and highest in the oldest age strata (60
years at index date; Table S6). We also considered the
lifetime cumulative probability of gout, assuming a
maximum lifespan of 80 years and adjusting for the
competing risk of death (using the technique of
modifying the survival analysis for which survival
age was used as the time scale as opposed to time in
study; Table S6).23,24 The lifetime probability of gout
was higher in donors versus healthy nondonors and
highest in the youngest age strata (20 years at index
date). For example, 1 in 5 (20.4%) donors whoTable 3. Risk Factors for Diagnosis of Gout in Living Kidney
Donors and Healthy Nondonors When Each Group Was
Analyzed Separately
Donors Healthy Nondonors
Age, per 5-y older 1.13 (1.01-1.26) 1.14 (1.09-1.20)
Female sex 0.45 (0.28-0.74) 0.28 (0.23-0.35)
Rural vs urban residence 0.78 (0.37-1.63) 0.98 (0.75-1.30)
Income, per each
quintile higher
0.94 (0.79-1.12) 1.01 (0.94-1.08)
Index date, per each
year more recent
0.98 (0.92-1.04) 0.99 (0.97-1.02)
Note: Separate Cox proportional hazards regression models
were created for living kidney donors and healthy nondonors.
Values are given as adjusted hazard ratio (95% confidence
interval).
Am J Kidney Dis. 2015;65(6):925-932donated at the age of 20 years were estimated to
receive a diagnosis of gout in their lifetime compared
to 1 in 10 healthy nondonors (10.9%) of the same age.
The estimated lifetime cumulative probability of gout
was similar in donors and nondonors from the general
population.
DISCUSSION
The increase in serum uric acid concentration after
donor nephrectomy is described in 2 recent studies.7,8
This prompted the current study, which to our
knowledge is the ﬁrst to describe the long-term risk of
gout in living kidney donors. We found that donors
have a higher relative risk of gout compared with
nondonors selected to have a similar level of baseline
health as donors. In absolute terms, the estimated
increase in the 20-year incidence of gout was small. It
is reassuring that a donor’s likelihood of developing
gout was not statistically greater than for the general
population.
Among our study’s strengths, it was made possible
because of Ontario’s universal health care beneﬁts,
with the collection of all health care encounters for all
citizens; concerns about selection biases are mini-
mized as a result. In addition, we manually reviewed
more than 2,000 perioperative medical charts, thereby
ensuring the accuracy of donor information presented.929
Table 4. Risk Factors for Diagnosis of Gout in Living Kidney
Donors, Considering Also Family History of Kidney Disease and
Predonation eGFR
Donors
Age, per 5-y older 1.09 (0.97-1.23)
Female sex 0.52 (0.32-0.86)
Rural vs urban residence 0.71 (0.34-1.50)
Income, per each quintile higher 0.93 (0.78-1.10)
Index date, per each year more recent 0.99 (0.93-1.05)
Family history of kidney disease 1.48 (0.84-2.62)
Predonation eGFRa
,80 mL/min/1.73 m2 1.63 (0.85-3.11)
80-89 mL/min/1.73 m2 1.91 (1.03-3.52)
Note: Cox proportional hazards regression model. Values are
given as adjusted hazard ratio (95% confidence interval).
Abbreviation: eGFR, estimated glomerular filtration rate.
aReference category is $ 90 mL/min/1.73 m2.
Lam et alFor the period of interest, this corresponds to all living
donation activity for Canada’s largest province. We
used techniques of restriction and matching so that
appropriate nondonors, with whom donor outcomes
could be reliably compared, were selected. We
matched donors and nondonors on risk factors asso-
ciated with gout, including older age and male sex.4,25
We followed up many people during a decade-long
span and for some, even for 20 years, with little
(,7%) loss to follow-up.
Our study also has some limitations. We relied on
administrative data collected for nonresearch pur-
poses, which limits the type of variables that are
available for inclusion and exclusion criteria and
the outcome measurements. Residual confounding
may affect our observed association between living
kidney donation and gout. Body mass index, over-
the-counter medication use, and dietary risk fac-
tors for gout, such as red meat consumption, were
unavailable in our data sources.26 Accurate racial
data were not available, but 71% of Ontario citizens
are white, as were w70% of donors. In the general
population, African Americans have a higher inci-
dence of gout compared with whites,27 and a recent
study suggests that this also may be true in the
donor population.28 Complete laboratory values for
serum uric acid and creatinine in follow-up were
not available in our data sources. We relied on
physician diagnoses, diagnostic codes, and outpa-
tient prescriptions to deﬁne our outcomes, which
may be subject to misclassiﬁcation. For the sec-
ondary analysis assessing the use of medications
typically used to treat gout, we did not have com-
plete information for donors younger than 65 years
and thus our analysis is limited to matched sets of
donors and nondonors who reached 65 years or
older in follow-up. It remains possible that an event
of gout more likely was ascertained in donors than930nondonors, although an additional analysis did not
support this ﬁnding. A prospective study comparing
living kidney donors with appropriate nondonor
controls in which all participants receive objective
assessments of gout is a preferred future method-
ology to corroborate our study ﬁndings.29
When deciding how to apply the study ﬁndings to
the more than 27,000 living kidney donations that
occur worldwide each year and to the care of
approximately half a million prior kidney donors, this
new information for the risk of gout should not deter
support for living donor kidney transplantation.30,31
Living kidney donation is an important and neces-
sary treatment option for those with kidney failure.
Although the ﬁnding of gout risk is biologically
plausible in living kidney donors, the study is not
without limitations, raising the possibility that the
true risk differs from our estimates of risk. We
recommend that this unique observation be corrob-
orated in future studies before it is shared routinely
with potential donors and their recipients as a step in
the informed consent process.32,33 Reassuringly, the
absolute increase in incidence of gout is small and
is unlikely to deter potential living kidney donors,
recipients, or transplantation programs from pro-
ceeding with donation.31 If high-quality evidence
that lifestyle modiﬁcations prevent gout becomes
available, living donors also can be encouraged to
follow such recommendations.34 For donors who
lack prescription drug coverage, reimbursing the
costs of medications used to manage gout could be
considered.35
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